에이프로젠바이오로직스

003060KOSPI의약품 제조업

54.8 / 100

Reference Date: 2026-07-24

Financial Score11.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure14.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 2.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen BioLogics operates two business segments: a pharmaceutical division producing synthetic drugs and a biopharmaceutical division manufacturing biologics. Its Cheongju-based Osong facility boasts world-class antibody production capacity, capable of producing over 2.8 million liters of culture media annually. The affiliated company Aprogen Pharma focuses on drug distribution, though the group reported an operating loss as of 2023.

Number of Employees

445people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

0.11Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE

-51.29Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

28.93Industry Average 12.430.0Point

2.3x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼7.1% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -35.2% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
지피씨알 대표 신동승 박사, 앱튼 지분 15% 취득
신동승 박사의 투자로 앱튼의 지분 확보와 지피씨알에 대한 추가 투자로 에이프로젠바이오로직스 자회사 앱튼의 성장 가능성이 높아졌다.
Positive
앱튼, 카티부스터 플랫폼 보유 '지피씨알' 최대주주 올라…파이프라인.....
에이프로젠바이오로직스의 자회사 앱튼이 지피씨알의 성장에 투자함으로써 기업 가치 상승 기대감 증가.
Positive
‘삼전닉스’보다 더 올랐다…상반기 708% 뛴 ‘이 종목’
에이프로젠바이오로직스의 상반기 수익률이 708% 상승하며, AI 인프라 관련 종목 중 상위권을 기록해 긍정적인 시장 반응을 보임.

Detailed Momentum

52-week position3.0Point

52w lower range (38%)

Current 2,090Won52-week high 5,10052-week low 235

1-month return4.0Point

1m +2.70% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 2Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-23
Positive주요사항보고서(유상증자결정)2026-07-14
Neutral주식등의대량보유상황보고서(일반)2026-07-07
Positive유상증자또는주식관련사채등의발행결과(자율공시)2026-07-01
Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-06-29